RU2010120536A - Pyridine and pyrazine derivatives useful for the treatment of cellular cellular disorders - Google Patents

Abstract

 1. The compound of formula I! ! in which W represents CH or N; ! J represents O or S; ! each of G1, G2, G3 and G4 is selected from CH and N, provided that no more than two of G1, G2, G3 and G4 are N; ! Ring A is selected from:! (1) phenyl substituted with R1 and optionally substituted with up to three groups of R2; or ! (2) a 5- or 6-membered monocyclic heteroaryl ring with up to three ring heteroatoms selected from oxygen, nitrogen, and sulfur, said ring being substituted with R1 and optionally substituted with up to three R2 groups; or ! (3) an 8-, 9- or 10-membered bicyclic ring system, possibly containing up to three ring heteroatoms selected from oxygen, nitrogen and sulfur, and optionally substituted with R1 and possibly substituted with up to three groups of R2; ! R1 is a group of the formula:! R4-X1-,! where X1 is a direct bond or is selected from O, S, SO, SO2, N (R5), CO, CH (OR5), CON (R5), N (R5) CO, N (R5) CON (R5), SO2N (R5), N (R5) SO2, C (R5) 2O, OC (R5) 2, C (R5) 2S, SC (R5) 2, C (R5) 2, C (R5) 2N (R5) and N (R5) N (R5) 2, where each R5 is independently selected from hydrogen, (1-8C) alkyl, hydroxy- (1-6C) alkyl, (1-6C) alkoxy- (1-6C) alkyl, cyano- ( 1-6C) alkyl, halo- (1-6C) alkyl, di - [(1-6C) alkyl] amino (1-6C) alkyl, (1-6C) alkylamino (1-6C) alkyl or amino (1-6C) alkyl, and when X1 is a direct bond or is selected from CH (OR5), C (R5) 2O, C (R5) 2S, C (R5) 2 or C (R5) 2N (R5), where R5 has any of the meanings defined above, then R4 is hydroxy- (1-6C) alkyl, (1-6C) alkoc and- (1-6C) alkyl, R5-S, R5-S (O), R5-SO2, R5-SO2-O, R5-S- (1-6C) alkyl, R5-S (O) - (1 -6C) alkyl, R5-SO2- (1-6C) alkyl, N, N-di (R5) sulfamoyl, N, N-di- (R5) sylphamoyl- (1-6C) alkyl, R5-SO2N (R5) , R5-SO2N (R5) - (1-6C) alkyl, R5-CON (R5), R5O-CON (R5), R5-CON (R5) - (1-6C) alkyl, R5O-CON (R5) - (1-6C) alkyl, (R5) 2N-SO2N (R5), (R5) 2N-SO2N (R5) - (1-6C) alkyl, (R5) 2N-CON (R5), (R5) 2N-CON (R5) - (1-6C) alkyl, R5-CO

Claims (18)

1. The compound of formula I

, in which W represents CH or N; J represents O or S; each of G ₁ , G ₂ , G ₃ and G _{4 is} selected from CH and N, provided that no more than two of G ₁ , G ₂ , G ₃ and G ₄ are N; ring A is selected from: (1) phenyl substituted with R ¹ and optionally substituted with up to three R ² groups; or (2) a 5- or 6-membered monocyclic heteroaryl ring with up to three ring heteroatoms selected from oxygen, nitrogen and sulfur, said ring being substituted with R ¹ and possibly substituted with up to three R ² groups; or (3) an 8-, 9-, or 10-membered bicyclic ring system, possibly containing up to three ring heteroatoms selected from oxygen, nitrogen, and sulfur, and optionally substituted with R ¹ and optionally substituted with up to three R ² groups; R ¹ represents a group of the formula: R ⁴ -X ¹ -, where X ¹ represents a direct bond or is selected from O, S, SO, SO ₂ , N (R ⁵ ), CO, CH (OR ⁵ ), CON (R ⁵ ), N (R ⁵ ) CO, N (R ⁵ ) CON (R ⁵ ), SO ₂ N (R ⁵ ), N (R ⁵ ) SO ₂ , C (R ⁵ ) ₂ O, OC (R ⁵ ) ₂ , C (R ⁵ ) ₂ S, SC (R ⁵ ) ₂ , C (R ⁵ ) ₂ , C (R ⁵ ) ₂ N (R ⁵ ) and N (R ⁵ ) N (R ⁵ ) ₂ , where each R ^{5 is} independently selected from hydrogen, (1-8C) alkyl, hydroxy- (1-6C) alkyl, (1-6C) alkoxy- (1-6C) alkyl, cyano- (1-6C) alkyl, halo- (1-6C) alkyl, di - [(1-6C) alkyl ] amino (1-6C) alkyl, (1-6C) alkylamino (1-6C) alkyl or amino (1-6C) alkyl, and when X ¹ is a direct bond or selected from CH (OR ⁵ ), C (R ⁵ ) ₂ O, C (R ⁵ ) ₂ S, C (R ⁵ ) ₂ or C (R ⁵ ) ₂ N (R ⁵ ), where R ⁵ has any of the meanings defined above, then R ^{4 is} presented is hydroxy- (1-6C) alkyl, (1-6C) alkoxy- (1-6C) alkyl, R ⁵ -S, R ⁵ -S (O), R ⁵ -SO ₂ , R ⁵ -SO ₂ - O, R ⁵ -S- (1-6C) alkyl, R ⁵ -S (O) - (1-6C) alkyl, R ⁵ -SO ₂ - (1-6C) alkyl, N, N-di (R ⁵ ) sulfamoyl, N, N-di- (R ⁵ ) sylphamoyl- (1-6C) alkyl, R ⁵ -SO ₂ N (R ⁵ ), R ⁵ -SO ₂ N (R ⁵ ) - (1-6C) alkyl , R ⁵ -CON (R ⁵ ), R ⁵ O-CON (R ⁵ ), R ⁵ -CON (R ⁵ ) - (1-6C) alkyl, R ⁵ O-CON (R ⁵ ) - (1-6C ) Alkyl, (R ⁵ ) ₂ N-SO ₂ N (R ⁵ ), (R ⁵ ) ₂ N-SO ₂ N (R ⁵ ) - (1-6C) Alkyl, (R ⁵ ) ₂ N-CON (R ⁵ ), (R ⁵ ) ₂ N-CON (R ⁵ ) - (1-6C) alkyl, R ⁵ -CO, R ⁵ -CO- (1-6C) alkyl, R ⁵ O-CO- (1-6C ) alkyl, (R ⁵ ) ₂ NCO, (R ⁵ ) ₂ NCO- (1-6C) alkyl, (R ⁵ ) ₂ N-COO, (R ⁵ ) ₂ NCO- (1-6C) alkyl, cyano, amino , (R ⁶ ) -amino, di- (R ⁶ ) -amino, amino (1-6C) alkyl, (R ⁶ ) -ammono (1-6C) alkyl or di- (R ⁶ ) amino ( 1-6C) alkyl, wherein each R ⁶ is present before nent is (1-6C) alkyl optionally substituted with 1, 2 or 3 substituents independently selected from halo, cyano, hydroxy and (1-6C) alkoxy; and when X ^{1 is} selected from O, S, SO, SO ₂ , N (R ⁵ ), CO, CON (R ⁵ ), N (R ⁵ ) CO, N (R ⁵ ) CON (R ⁵ ), SO ₂ N (R ⁵ ), N (R ⁵ ) SO ₂ , OC (R ⁵ ) ₂ , SC (R ⁵ ) ₂ and N (R ⁵ ) C (R ⁵ ) ₂ , where R ⁵ has any of the meanings defined above, then R ⁴ represents hydroxy- (1-6C) alkyl, (1-6C) alkoxy- (1-6C) alkyl, R ⁵ -S- (1-6C) alkyl, R ⁵ -S (O) (1- 6C) alkyl, R ⁵ -SO ₂ - (1-6C) alkyl, N, N-di- (R ⁵ ) sylphamoyl- (1-6C) alkyl, R ⁵ -SO ₂ N (R ⁵ ) - (1- 6C) Alkyl, R ⁵ -CON (R ⁵ ) - (1-6C) Alkyl, R ⁵ O-CON (R ⁵ ) - (1-6C) alkyl, (R ⁵ ) ₂ N-SO ₂ N (R ⁵ ) - (1-6C) alkyl, (R ⁵ ) ₂ N-CON (R ⁵ ) - (1-6C) alkyl, R ⁵ -CO, R ⁵ -CO- (1-6C) alkyl, R ⁵ O- CO, R ⁵ O-CO- (1-6C) alkyl, (R ⁵ ) ₂ NCO, (R ⁵ ) ₂ NCO- (1-6C) alkyl, (R ⁵ ) ₂ NCOO- (1-6C) alkyl, amino (1-6C) alkyl, (R ⁶ ) amino (1-6C) alkyl or di- (R ⁶ ) amino (1-6C) alkyl, where each the present R ⁶ is (1-6C) alkyl, optionally substituted with 1, 2 or 3 substituents independently selected from halo, cyano, hydroxy and (1-6C) alkoxy; or R ¹ represents a group of the formula: Q ¹ -X ² -, where X ² represents a direct bond or is selected from O, S, SO, SO ₂ , N (R ⁷ ), N [C (O) R ⁷ ], N [C (O) N (R ⁷ ) ₂ ], N [C (O) OR ⁷ ], N [SO ₂ —N (R ⁷ ) ₂ ], CO, CH (OR ⁷ ), CON (R ⁷ ), N (R ⁷ ) CO, N (R ⁷ ) CON ( R ⁷ ), SO ₂ N (R ⁷ ), N (R ⁷ ) SO ₂ , O-SO ₂ , SO ₂ -O, C (R ⁷ ) ₂ O, OC (R ⁷ ) ₂ , C (R ⁷ ) ₂ S, SC (R ⁷ ) ₂ , C (R ⁷ ) ₂ , C (R ⁷ ) ₂ N (R ⁷ ) and N (R ⁷ ) C (R ⁷ ) ₂ , where each R ^{7 is} independently selected from hydrogen, (1-8C) alkyl, hydroxy- (1-6C) alkyl, (1-6C) alkoxy- (1-6C) alkyl, cyano- (1-6C) alkyl, halo- (1-6C) alkyl, di- (R ⁸ ) amino (1-6C) alkyl, (R ⁸ ) amino (1-6C) alkyl, or amino (1-6C) alkyl, where R ⁸ is (1-6C) alkyl, optionally substituted 1, 2 or 3 substituents independently selected from halogen, cyano, hydr Xi and (1-6C) alkoxy; and Q ¹ represents aryl, aryl- (1-6C) alkyl, (3-8C) cycloalkyl, (3-8C) cycloalkyl- (1-6C) alkyl, heterocyclyl, heterocyclyl- (1-6C) alkyl, heteroaryl or heteroaryl- (1-6C) alkyl, where any aryl or (3-8C) cycloalkyl group in the substituent R ¹ carries 1, 2 or 3 substituents, and any heterocycle alkyl or heteroaryl group in the substituent R ¹ possibly carries 1, 2 or 3 substituents, wherein said substituents are independently selected from halo, trifluoromethyl, cyano, nitro, hydroxy, amino, carboxy, carbamoyl, ureido, (1-8C) alkyl, (2-8C) alkenyl, (2-8C) alkynyl a, (1-6C) alkoxy, halo- (1-6C) alkoxy, hydroxy- (1-6C) alkyl, (1-6C) alkoxy- (1-6C) alkyl, (1-6C) alkylsulfonyl- (1 -6C) alkyl, cyano- (1-6C) alkyl, halo- (1-6C) alkyl, amino (1-6C) alkyl, (1-6C) alkylamino (1-6C) alkyl, di - [( 1-6C) alkyl] amino (1-6C) alkyl, (2-6C) alkenyloxy, (2-6C) alkynyloxy, (1-6C) alkylthio, (1-6C) alkylsulfinyl, (1-6C) alkylsulfonyl, (1-6C) alkylamino, di - [(1-6C) alkyl] amino, (1-6C) alkoxycarbonyl, (2-6C) alkanoyl, hydroxy- (2-6C) alkanoyl, (1-6C) alkoxy- ( 2-6C) alkanoyl, (2-6C) alkanoyloxy, N- (1-6C) alkylcarbamoyl, N, N-di - [(1-6C) alkyl] carbamoyl, carbamoyl- (1-6C) alkyl, N- ( 1-6C) alkylcarbamo il- (1-6C) alkyl, N, N-di - [(1-6C) alkyl] carbamoyl- (1-6C) alkyl, (1-6C) alkanoylamino, N- (1-6C) alkyl- (1 -6C) alkanoylamino, N- (1-6C) alkylureido, N '- (1-6C) alkylureido, N', N'-di - [(1-6C) alkyl] ureido, N, N'-di- [ (1-6C) alkyl] ureido, N, N ', N'-tri - [(1-6C) alkyl] ureido, N- (1-6C) alkylsulfamoyl, N, N-di - [(1-6C) alkyl] sulfamoyl, (1-6C) alkanesulfonylamino, N- (1-6C) alkyl- (1-6C) alkanesulfonylamino, (1-6C) alkoxy- (1-6C) alkoxycarbonyl, (1-6C) alkylamino (2 -6C) alkanoyl, di - [(1-6C) alkyl] amino (2-6C) alkanoyl, (1-6C) alkanoylamino (2-6C) alkanoyl, (1-6C) alkoxy- (1-6C) alkoxy- (2-6C) alkanoyl, heterocyclyl, heterocyclyl- (1-6C) alkyl, heteroary or a heteroaryl- (1-6C) alkyl, and any heterocyclyl substituent group of R ¹ may bear 1 or 2 oxo substituent; where any CH, CH ₂ , or CH ₃ in the composition of any alkyl group present in the definition of R ⁴ that is attached to X ¹ , or present in the definition of Q ¹ that is attached to X ² , possibly carries a hydroxy or cyano group and possibly carries up to up to three halo groups, and may possibly be replaced by an atom selected from O, S or N, or a SO ₂ group, and adjacent carbon atoms in the alkyl chain may possibly be separated by inserting a C≡C group in this chain; R ² groups may be the same or different, and each of them is selected from halogen, cyano, hydroxy, amino, (1-8C) alkyl, (2-8C) alkenyl, (2-8C) alkynyl, (1-6C) alkoxy , (2-6C) alkenyloxy, (2-6C) alkynyloxy, halo- (1-6C) alkoxy, (1-6C) alkylthio, (1-6C) alkylsulfinyl, (1-6C) alkylsulfonyl, (1-6C) alkylamino, di - [(1-6C) alkyl] amino, (1-6C) alkoxycarbonyl, (2-6C) alkanoyl, (2-6C) alkanoyloxy, carbamoyl, N- (1-6C) alkylcarbamoyl, N, N- di - [(1-6C) alkyl] carbamoyl, (1-6C) alkanoylamino, N- (1-6C) alkyl- (1-6C) alkanoylamino, (1-6C) alkoxy- (1-6C) alkyl, hydroxy - (1-6C) alkyl, amino (1-6C) alkyl, (1-6C) alkylamino (1-6C) alkyl, di - [(1-6C) alkyl] amino (1-6C) alkyl, (1-6C) alkoxy- (1-6C) alkoxy, hydroxy- (1-6C) alkoxy, amino - (1-6C) alkoxy, (1-6C) alkylamino (1-6C) alkoxy and di - [(1-6C) alkyl] amino (1-6C) alkoxy; n is 0, 1, 2 or 3, and when n is 2 or 3, the R ³ groups may be the same or different, and each R ³ group present is selected from hydrogen, halogen, amino, cyano, sulfamoyl, OR ⁹ , N- (1-6C) alkylsulfamoyl, N, N-di - [(1-6C) alkyl] sulfamoyl, trifluoromethyl, (1-8C) alkyl, (2-8C) alkenyl, (2-8C) alkynyl, (1-6C ) alkoxy, (1-6C) alkoxycarbonyl, halo- (1-6C) alkoxy, carbamoyl, N- (1-6C) alkylcarbamoyl, N, N-di - [(1-6C) alkyl] carbamoyl, (1-6C ) alkanoylamino, (1-6C) alkylthio, (1-6C) alkylsulfinyl, (1-6C) alkylsulfonyl, hydroxy- (1-6C) alkyl, (1-6C) alkoxy- (1-6C) alkyl, (2- 6C) alkanoyl, (1-6C) alkane sulfonylamino, amino (1-6C) alkyl, (1-6C) alkylamino (1-6C) alkyl, di - [(1-6C) alkyl] amino (1-6C) alkyl, (1-6C) alkoxy - (1-6C) alkoxy, hydroxy- (1-6C) alkoxy, amino (1-6C) alkoxy, (1-6C) alkylamino (1-6C) alkoxy and di - [(1-6C) alkyl] amino (1-6C) alkoxy, where R ⁹ is fluoro- (1-6C) alkyl, aryl, aryl- (1-6C) alkyl, heterocyclyl, heterocycpyl- (1-6C) alkyl, heteroaryl or heteroaryl- ( 1-6C) alkyl, where any aryl, heterocyclyl or heteroaryl group in the definition of R ⁹ may bear 1, 2 or 3 substituents independently selected from halogeno, fluoro- (1-6C) alkyl, oxo, cyano, hydroxy, am but, carboxy, carbamoyl, (1-8C) alkyl, (2-8S) alkenyl, (2-8S) alkynyl or (1-6C) alkoxy; or a pharmaceutically acceptable salt thereof. 2. The compound of formula I according to claim 1, where ring A is selected from: (1) phenyl substituted with R ¹ and optionally substituted with an R ² group; or (2) up to three 5- or 6-membered monocyclic heteroaryl ring with ring nitrogen atoms, said ring being substituted with R ¹ and possibly substituted with an R ² group; or (3) an 8-, 9-, or 10-membered bicyclic ring system, where the ring attached to the central main pyridinyl ring is a phenyl or monocyclic heteroaryl ring, and where said bicyclic ring system possibly contains up to two ring heteroatoms selected from oxygen and nitrogen, and optionally substituted with R ¹ and optionally substituted with an R ² group; or a pharmaceutically acceptable salt thereof. 3. The compound of formula I according to claim 1, where R ¹ represents a group of the formula: R ⁴ -X ¹ -, where X ¹ represents a direct bond or is selected from O, SO, SO ₂ , N (R ⁵ ), CO, CON (R ⁵ ), N (R ⁵ ) CO, SO ₂ N (R ⁵ ), N (R ⁵ ) SO ₂ , C (R ⁵ ) ₂ O, OC (R ⁵ ) ₂ , C (R ⁵ ) ₂ , C (R ⁵ ) ₂ N (R ⁵ ) and N (R ⁵ ) C (R ⁵ ) ₂ , where each R ⁵ independently selected from hydrogen or (1-8C) alkyl, and when X ¹ is a direct bond or is selected from C (R ⁵ ) ₂ O, C (R ⁵ ) ₂ or C (R ⁵ ) ₂ N (R ⁵ ), where R ⁵ has any of the meanings defined above, then R ⁴ represents hydroxy- (1-6C) alkyl, (1-6C) alkoxy- (1-6C) alkyl, R ⁵ -S, R ⁵ -S (O), R ⁵ -SO ₂ , R ⁵ -SO _2- O, R ⁵ -S- (1-6C) alkyl, R ⁵ - (O) - (1-6C) alkyl, R ⁵ -SO ₂ - (1-6C) alkyl, N, N-di (R ⁵ ) sulfamoyl, N, N-di- (R ⁵ ) sylphamoyl- (1-6C) alkyl, R ⁵ -SO ₂ N (R ⁵ ), R ⁵ -SO ₂ - (1-6C) alkyl, R ⁵ - CON (R ⁵ ), R ⁵ —CON (R ⁵ ) - (1-6C) alkyl, R ⁵ —CO, R ⁵ —CO— (1-6C) alkyl, (R ⁵ ) ₂ NCO, (R ⁵ ) ₂ NCO- (1-6C) alkyl, cyano, amino, (R ⁶ ) amino, di- (R ⁶ ) amino, amino (1-6C) alkyl, (R ⁶ ) amino- (1-6C ) alkyl or di- (R ⁶ ) amino (1-6C) alkyl, where each R ⁶ present is pr is (1-6C) alkyl; and when X ^{1 is} selected from O, SO, SO ₂ , N (R ⁵ ), CO, CON (R ⁵ ), N (R ⁵ ) CO, SO ₂ N (R ⁵ ), N (R ⁵ ) SO ₂ , OC (R ⁵ ) ₂ and N (R ⁵ ) C (R ⁵ ) ₂ , where R ⁵ has any of the meanings defined above, then R ⁴ is hydroxy- (1-6C) alkyl, (1-6C) alkoxy - (1-6C) alkyl, R ⁵ -S- (1-6C) alkyl, R ⁵ -S (O) - (1-6C) alkyl, R ⁵ -SO ₂ - (1-6C) alkyl, R ⁵ -CON (R ⁵ ) - (1-6C) alkyl, R ⁵ -CO- (1-6C) alkyl, (R ⁵ ) ₂ NCO- (1-6C) alkyl, amino (1-6C) alkyl, ( R ⁶ ) -amino (1-6C) alkyl or di- (R ⁶ ) -amino- (1-6C) alkyl, where each R ⁶ present is (1-6C) alkyl; or R ¹ represents a group of the formula: Q ¹ -X ² -, where X ² represents a direct bond or is selected from O, SO, SO ₂ , N (R ⁷ ), N [C (O) R ⁷ ], N [C (O) N (R ⁷ ) ₂ ], N [C (O) OR ⁷ ], N [SO ₂ —N (R ⁷ ) ₂ ], CO, CON (R ⁷ ), N (R ⁷ ) CO, SO ₂ N (R ⁷ ), N (R ⁷ ) SO ₂ , O-SO ₂ , SO ₂ -O, C (R ⁷ ) ₂ O, OC (R ⁷ ) ₂ , C (R ⁷ ) ₂ , C (R ⁷ ) ₂ N (R ⁷ ) and N (R ⁷ ) C (R ⁷ ) ₂ , where each R ^{7 is} independently selected from hydrogen or (1-8C) alkyl; and Q ¹ represents heterocyclyl, heterocyclyl- (1-6C) alkyl, heteroaryl or heteroaryl- (1-6C) alkyl, where any heterocyclyl or heteroaryl group in the substituent R ¹ possibly carries 1, 2 or 3 substituents, where these substituents independently selected from halo, trifluoromethyl, cyano, hydroxy, amino, carboxy, (1-8C) alkyl, (2-8C) alkenyl, (2-8C) alkynyl, (1-6C) alkoxy, halo- (1-6C) alkoxy, hydroxy- (1-6C) alkyl, (1-6C) alkoxy- (1-6C) alkyl, cyano- (1-6C) alkyl, halo- (1-6C) alkyl, amino (1-6C) alkyl, (1-6C) alkylamino (1-6C) alkyl, di - [(1-6C) alkyl] amino (1-6C) al kila, (1-6C) alkylsulfonyl, (1-6C) alkylamino, di - [(1-6C) alkyl] amino, (1-6C) alkoxycarbonyl, N- (1-6C) alkylcarbamoyl, (1-6C) alkanoylamino , (2-6C) alkanoyl, hydroxy- (2-6C) alkanoyl, (1-6C) alkoxy- (2-6C) alkanoyl, carbamoyl- (1-6C) alkyl, N- (1-6C) alkylcarbamoyl- ( 1-6C) alkyl, N, N-di - [(1-6C) alkyl] carbamoyl- (1-6C) alkyl, (1-6C) alkoxy- (1-6C) alkoxycarbonyl, (1-6C) alkylamino (2-6C) alkanoyl, di - [(1-6C) alkyl] amino (2-6C) alkanoyl, (1-6C) alkanoylamino (2-6C) alkanoyl, (1-6C) alkoxy- (1- 6C) alkoxy- (2-6C) alkanoyl, heterocyclyl, heterocyclyl- (1-6C) alkyl, heteroaryl or heteroaryl- (1-6C) alkyl, and any hetero the cyclic group of R ¹ may optionally carry 1 or 2 oxo substituents; where any CH, CH ₂ , or CH ₃ in any alkyl group present in the definition of R ⁴ that is attached to X ¹ or present in the definition of Q ¹ that is attached to X ² can possibly be replaced by an O atom or an SO ₂ group , and adjacent carbon atoms in the alkyl chain may possibly be separated by the insertion of a C≡C group; or a pharmaceutically acceptable salt thereof. 4. The compound of formula I according to claim 1, where the R ² groups can be the same or different, and each of them is selected from halogen, cyano, (1-8C) alkyl, (2-8C) alkenyl, (2-8C) alkynyl , (1-6C) alkoxy, (2-6C) alkenyloxy, (2-6C) alkynyloxy, fluoro- (1-6C) alkoxy, (1-6C) alkylthio, (1-6C) alkylsulfinyl, (1-6C) alkylsulfonyl, (1-6C) alkylamino, di - [(1-6C) alkyl] amino, (2-6C) alkanoyl, carbamoyl, N- (1-6C) alkylcarbamoyl, N, N-di - [(1-6C) ) alkyl] carbamoyl, (1-6C) alkanoylamino, N- (1-6C) alkyl- (1-6C) alkanoylamino, (1-6C) alkoxy- (1-6C) alkyl, amino (1-6C) alkyl , (1-6C) alkylamino (1-6C) alkyl, di - [(1-6C) alkyl] amino (1-6C) alkyl, hydroxyl and- (1-6C) alkyl, (1-6C) alkoxy- (1-6C) alkoxy or hydroxy- (1-6C) alkoxy; or a pharmaceutically acceptable salt thereof. 5. The compound of formula I according to claim 1, where n is 0, 1 or 2, and when n is 2, the R ³ groups may be the same or different, and each R ³ group present is selected from hydrogen, halogen, cyano, OR ⁹ , trifluoromethyl, (1-8C) alkyl, (2-8C) alkenyl, (2-8C) alkynyl, (1-6C) alkoxy, halo- (1-6C) alkoxy, carbamoyl, N- (1-6C) alkylcarbamoyl , N, N-di - [(1-6C) alkyl] carbamoyl, (1-6C) alkanoylamino, (1-6C) alkylthio, (1-6C) alkylsulfinyl, (1-6C) alkylsulfonyl, hydroxy- (1- 6C) alkyl, (1-6C) alkoxy- (1-6C) alkyl, (2-6C) alkanoyl, (1-6C) alkanesulfonylamino, (1-6C) alkoxy- (1-6C) alkoxy, hydroxy- (1 -6C) alkoxy, amino - (1-6C) alkoxy, (1-6C) alkylamino (1-6C) alkoxy and di - [(1-6C) alkyl] amino (1-6C) alkoxy, where R ⁹ is fluoro- (1 -6C) alkyl; or a pharmaceutically acceptable salt thereof. 6. The compound of formula I according to claim 1, where: W represents CH or N; J represents O; each of G ₁ , G ₂ , G ₃ and G _{4 is} selected from CH and N, provided that no more than two of G ₁ , G ₂ , G ₃ and G ₄ are N; ring A is selected from: (1) phenyl substituted with R ¹ and optionally substituted with an R ² group; or (2) up to three 5- or 6-membered monocyclic heteroaryl ring with ring nitrogen atoms, said ring being substituted with R ¹ and possibly substituted with an R ² group; or (3) an 8-, 9-, or 10-membered bicyclic ring system, where the ring attached to the central main pyridinyl ring is a phenyl or monocyclic heteroaryl ring, and where said bicyclic ring system possibly contains up to two ring heteroatoms selected from oxygen and nitrogen, and optionally substituted with R ¹ and optionally substituted with an R ² group; R ¹ represents a group of the formula: R ⁴ -X ¹ -, where X ¹ represents a direct bond or is selected from O, SO, SO ₂ , N (R ⁵ ), CO, CON (R ⁵ ), N (R ⁵ ) CO, SO ₂ N (R ⁵ ), N (R ⁵ ) SO ₂ , C (R ⁵ ) O, OC (R ⁵ ), C (R ⁵ ) ₂ , C (R ⁵ ) ₂ N (R ⁵ ) and N (R ⁵ ) C (R ⁵ ) ₂ , where each R ^{5 is} independently selected from hydrogen or (1-8C) alkyl, and when X ¹ is a direct bond or is selected from C (R ⁵ ) ₂ O, C (R ⁵ ) ₂ or C (R ⁵ ) ₂ N (R ⁵ ), where R ⁵ has any of the meanings defined above, then R ⁴ represents hydroxy- (1-3C) alkyl, (1-6C) alkoxy- (1-3C) alkyl, R ⁵ -S, R ⁵ -S (O), R ⁵ -SO ₂ , R ⁵ -SO _2- O, R ⁵ -S- (1-3C) alkyl, R ⁵ -S (O) - (1-3C) alkyl, R ⁵ -SO ₂ - (1-3C) alkyl, N, N-di- (R ⁵ ) sulfamoyl, N, N-di- (R ⁵ ) sylphamoyl- (1-3C) alkyl, R ⁵ -SO ₂ N (R ⁵ ), R ⁵ -SO ₂ N (R ⁵ ) - (1- 3C) alkyl, R ⁵ —CON (R ⁵ ), R ⁵ —CON (R ⁵ ) - (1-3C) alkyl, R ⁵ —CO, R ⁵ —CO— (1-3C) alkyl, (R ⁵ ) ₂ NCO, (R ⁵ ) ₂ NCO- (1-3C) alkyl, cyano, amino, (R ⁶ ) amino, di- (R ⁶ ) amino, amino (1-3C) alkyl, (R ⁶ ) -amino- (1-3C) alkyl or di (R ⁶⁾ -amino- (1-3C) alkyl, wherein each attending nd R ⁶ represents (1-3C) alkyl; and when X ^{1 is} selected from O, SO, SO ₂ , N (R ⁵ ), CO, CON (R ⁵ ), N (R ⁵ ) CO, SO ₂ N (R ⁵ ), N (R ⁵ ) SO ₂ , OC (R ⁵ ) ₂ and N (R ⁵ ) C (R ⁵ ) ₂ , where R ⁵ has any of the meanings defined above, then R ⁴ is hydroxy- (1-3C) alkyl, (1-6C) alkoxy - (1-3C) alkyl, R ⁵ -S- (1-3C) alkyl, R ⁵ -S (O) - (1-3C) alkyl, R ⁵ -SO ₂ - (1-3C) alkyl, R ⁵ -CON (R ⁵ ) - (1-3C) alkyl, R ⁵ -CO- (1-3C) alkyl, (R ⁵ ) ₂ NCO- (1-3C) alkyl, amino (1-3C) alkyl, ( R ⁶ ) -amino- (1-3C) alkyl or di- (R ⁶ ) -amino- (1-3C) alkyl, where each R ⁶ present is (1-3C) alkyl; or R ¹ represents a group of the formula: Q ¹ -X ² -, where X ² represents a direct bond or is selected from O, SO, SO ₂ , N (R ⁷ ), N [C (O) R ⁷ ], N [C (O) N (R ⁷ ) ₂ ], N [C (O) OR ⁷ ], N [SO ₂ —N (R ⁷ ) ₂ ], CO, CON (R ⁷ ), N (R ⁷ ) CO, SO ₂ N (R ⁷ ), N (R ⁷ ) SO ₂ , O-SO ₂ , SO ₂ -O, C (R ⁷ ) O, OC (R ⁷ ) ₂ , C (R ⁷ ) ₂ , C (R ⁷ ) ₂ N (R ⁷ ) and N (R ⁷ ) C (R ⁷ ) ₂ , where each R ^{7 is} independently selected from hydrogen or (1-8C) alkyl; and Q ¹ represents heterocyclyl, heterocyclyl- (1-3C) alkyl, heteroaryl or heteroaryl- (1-3C) alkyl, wherein said heterocyclyl or heterocyclyl in the heterocyclyl- (1-3C) alkyl group is selected from piperidinyl, pyrrolidinyl, morpholinyl , piperazinyl, tetrahydro-2H-pyranyl, azetidinyl, 1,1-dioxotetrahydro-1,4-thiazinyl, imidazolinyl, azepanil, 1H-imidazolyl, 1,4-diazepanyl, (1R, 5S) -8-azabicycpo [3.2.1 ] octanyl, quinuclidinyl, (3R) -quinuclidinyl, 3,4,4a, 5,6,7,8,8a-octahydro-2H-quinolinyl, 3,4,6,7,8,8a-hexahydro-1H-pyrrolo [2,1-c] pyrazinyl, 3,8-diazaspiro [5.5] undecanyl a, 2,8-diazaspiro [4.5] decanyl, 4,9-diazaspiro [5.5] undecanyl, 2,3,3a, 4,6,6a-hexahydro-1H-pyrrolo [3,4-c] pyrrolyl, 3, 9-diazaspiro [5.5] undecanyl and (1S, 4S) -3,6-diazabicyclo [2.2.1] heptanyl, and said heteroaryl or heteroaryl in the heteroaryl- (1-3C) alkyl group is pyrazolyl, each of which is possible carries halogen, trifluoromethyl, cyano, hydroxy, amino, carboxy, (1-8C) alkyl, (2-8C) alkenyl, (2-8C) alkynyl, (1-6C) alkoxy, halo- (1-6C) alkoxy, hydroxy- (1-6C) alkyl, (1-6C) alkoxy- (1-6C) alkyl, cyano- (1-6C) alkyl, halo- (1-6C) alkyl, amino (1-6C) alkyl, (1-6C) alkylamino (1-6C) alkyl, di - [(1-6C) alkyl] amino (1-6C) alkyl, (1-6C) alkylsulfonyl, (1-6C) alkylamino, di - [(1-6C) alkyl] amino, (1- 6C) alkoxy carbonyl, N- (1-6C) alkylcarbamoyl, (1-6C) alkanoylamino, (2-6C) alkanoyl, hydroxy- (2-6C) alkanoyl, (1-6C) alkoxy- (2-6C) alkanoyl, carbamoyl- (1-6C) alkyl, N- (1-6C) alkylcarbamoyl- (1-6C) alkyl, N, N-di - [(1-6C) alkyl] carbamoyl- (1-6C) alkyl, (1-6C) alkoxy- (1-6C) alkoxycarbonyl, (1-6C) alkylamino (2-6C) alkanoyl, di - [(1-6C) alkyl] amino (2-6C) alkanoyl, (1- 6C) alkanoylamino- (2-6C) alkanoyl, (1-6C) alkoxy- (1-6C) alkoxy- (2-6C) alkanoyl, heterocyclyl, heterocyclyl- (1-6C) alkyl, heteroaryl or heteroaryl- (1- 6C) alkyl, and any heterocyclyl group in the substituent R ¹ may be 1 or 2 oxo; where any CH, CH ₂ , or CH ₃ in any alkyl group present in the definition of R ⁴ that is attached to X ¹ or present in the definition of Q ¹ that is attached to X ² may possibly be replaced by an O atom or an SO ₂ group , and adjacent carbon atoms in the alkyl chain may possibly be separated by the insertion of C≡C groups in this chain; R ^{2 is} selected from halo, cyano, (1-8C) alkyl, (1-6C) alkoxy, (1-6C) alkylthio, (2-6C) alkanoyl, (1-6C) alkylamino, carbamoyl, N- (1- 6C) alkylcarbamoyl, N, N-di - [(1-6C) alkyl] carbamoyl, (1-6C) alkoxy- (1-6C) alkyl, hydroxy- (1-6C) alkyl, (1-6C) alkoxy- (1-6C) alkoxy, (1-6C) alkylamino (1-6C) alkyl or hydroxy- (1-6C) alkoxy; n is 0, 1 or 2, and when n is 2, the R ³ groups may be the same or different, and each R ³ group present is selected from hydrogen, fluoro, bromo, chloro, cyano, hydroxymethyl, methylcarbamoyl, OR ⁹ , trifluoromethyl, methyl or propyl, where R ⁹ represents methyl or trifluoromethyl; or a pharmaceutically acceptable salt thereof. 7. The compound of formula I according to claim 1, where: W represents CH or N; J represents O; each of G ₁ , G ₂ , G ₃ and G _{4 is} selected from CH and N, provided that no more than two of G ₁ , G ₂ , G ₃ and G ₄ are N; ring A is selected from: (1) phenyl substituted with R ¹ and optionally substituted with an R ² group; or (2) pyrazolyl, pyridinyl, thienyl, thiazolyl or 1H-1,2,3-triazolyl, wherein said ring is substituted with R ¹ and optionally substituted with an R ² group; or (3) naphthyl, quinolyl, 2,3-dihydro-1,4-benzodioxinyl, 1H-indazolyl, 1H-indolyl or 1,3-benzodioxolyl, wherein said bicyclic ring system is optionally substituted with R ¹ and optionally substituted with R ² ; R ¹ represents a group of the formula: R ⁴ -X ¹ -, where X ¹ represents a direct bond or is selected from O, SO, SO ₂ , N (R ⁵ ), CO, CON (R ⁵ ), N (R ⁵ ) CO, SO ₂ N (R ⁵ ), N (R ⁵ ) SO ₂ , C (R ⁵ ) ₂ O, OC (R ⁵ ) ₂ , C (R ⁵ ) ₂ , C (R ⁵ ) ₂ N (R ⁵ ) and N (R ⁵ ) C (R ⁵ ) ₂ , where each R ⁵ independently selected from hydrogen or (1-8C) alkyl, and when X ¹ is a direct bond or is selected from C (R ⁵ ) ₂ O, C (R ⁵ ) ₂ or C (R ⁵ ) ₂ N (R ⁵ ), where R ⁵ has any of the meanings defined above, then R ⁴ represents hydroxy- (1-3C) alkyl, (1-6C) alkoxy- (1-3C) alkyl, R ⁵ -S, R ⁵ -S (O), R ⁵ -SO ₂ , R ⁵ -SO _2- O, R ⁵ -S- (1-3C) alkyl, R ⁵ -S (O) - (1-3C) alkyl, R ⁵ -SO ₂ - (1-3C) alkyl, N, N-di- (R ⁵ ) sulfamoyl, N, N-di- (R ⁵ ) sylphamoyl- (1-3C) alkyl, R ⁵ -SO ₂ N (R ⁵ ), R ⁵ -SO ₂ N (R ⁵ ) - (1- 3C) alkyl, R ⁵ —CON (R ⁵ ), R ⁵ —CON (R ⁵ ) - (1-3C) alkyl, R ⁵ —CO, R ⁵ —CO— (1-3C) alkyl, (R ⁵ ) ₂ NCO, (R ⁵ ) ₂ NCO- (1-3C) alkyl, cyano, amino, (R ⁶ ) amino, di- (R ⁶ ) amino, amino (1-3C) alkyl, (R ⁶ ) -amino- (1-3C) alkyl or di (R ⁶⁾ -amino- (1-3C) alkyl, wherein each present in person R ⁶ represents (1-3C) alkyl; and when X ^{1 is} selected from O, SO, SO ₂ , N (R ⁵ ), CO, CON (R ⁵ ), N (R ⁵ ) CO, SO ₂ N (R ⁵ ), N (R ⁵ ) SO ₂ , OC (R ⁵ ) ₂ and N (R ⁵ ) C (R ⁵ ) ₂ , where R ⁵ has any of the meanings defined above, then R ⁴ is hydroxy- (1-3C) alkyl, (1-6C) alkoxy - (1-3C) alkyl, R ⁵ -S- (1-3C) alkyl, R ⁵ -S (O) - (1-3C) alkyl, R ⁵ -SO ₂ - (1-3C) alkyl, R ⁵ -CON (R ⁵ ) - (1-3C) alkyl, R ⁵ -CO- (1-3C) alkyl, (R ⁵ ) ₂ NCO- (1-3C) alkyl, amino (1-3C) alkyl, ( R ⁶ ) -amino- (1-3C) alkyl or di- (R ⁶ ) -amino- (1-3C) alkyl, where each R ⁶ present is (1-3C) alkyl; or R ¹ represents a group of the formula: Q ¹ -X ² -, where X ² represents a direct bond or is selected from O, SO, SO ₂ , N (R ⁷ ), N [C (O) R ⁷ ], N [C (O) N (R ⁷ ) ₂ ], N [C (O) OR ⁷ ], N [SO ₂ —N (R ⁷ ) ₂ ], CO, CON (R ⁷ ), N (R ⁷ ) CO, SO ₂ N (R ⁷ ), N (R ⁷ ) SO ₂ , O-SO ₂ , SO ₂ -0, C (R ⁷ ) ₂ O, OC (R ⁷ ) ₂ , C (R ⁷ ) ₂ , C (R ⁷ ) ₂ N (R ⁷ ) and N (R ⁷ ) C (R ⁷ ) ₂ , where each R ^{7 is} independently selected from hydrogen or (1-8C) alkyl; and Q ¹ represents heterocyclyl, heterocyclyl- (1-3C) alkyl, heteroaryl or heteroaryl- (1-3C) alkyl, wherein said heterocyclyl or heterocyclyl in the heterocyclyl- (1-3C) alkyl group is selected from piperidinyl, pyrrolidinyl, morpholinyl , piperazinyl, tetrahydro-2H-pyranyl, azetidinyl, 1,1-dioxotetrahydro-1,4-thiazinyl, imidazolinyl, azepanyl, 1H-imidazolyl, 1,4-diazepanyl, (1R, 5S) -8-azabicyclo [3.2.1 ] octanyl, quinuclidinyl, (3R) -quinuclidinyl, 3,4,4a, 5,6,7,8,8a-octahydro-2H-quinolinyl, 3,4,6,7,8,8a-hexahydro-1H-pyrrolo [2,1-c] pyrazinyl, 3,8-diazaspiro [5.5] undecane la, 2,8-diazaspiro [4.5] decanyl, 4,9-diazaspiro [5.5] undecanyl, 2,3,3a, 4,6,6a-hexahydro-1H-pyrrolo [3,4-c] pyrrolyl, 3, 9-diazaspiro [5.5] undecanyl and (1S, 4S) -3,6-diazabicyclo [2.2.1] heptanyl, and said heteroaryl or heteroaryl in the heteroaryl- (1-3C) alkyl group is pyrazolyl, each of which is possible carries halogen, trifluoromethyl, cyano, hydroxy, amino, carboxy, (1-8C) alkyl, (2-8C) alkenyl, (2-8C) alkynyl, (1-6C) alkoxy, halo- (1-6C) alkoxy, hydroxy- (1-6C) alkyl, (1-6C) alkoxy- (1-6C) alkyl, cyano- (1-6C) alkyl, halo- (1-6C) alkyl, amino (1-6C) alkyl, (1-6C) alkylamino (1-6 ) alkyl, di - [(1-6C) alkyl] amino (1-6C) alkyl, (1-6C) alkylsulfonyl, (1-6C) alkylamino, di - [(1-6C) alkyl] amino, (1 -6C) alkoxy carbonyl, N- (1-6C) alkylcarbamoyl, (1-6C) alkanoylamino, (2-6C) alkanoyl, hydroxy- (2-6C) alkanoyl, (1-6C) alkoxy- (2-6C ) alkanoyl, carbamoyl- (1-6C) alkyl, N- (1-6C) alkylcarbamoyl- (1-6C) alkyl, N, N-di - [(1-6C) alkyl] carbamoyl- (1-6C) alkyl , (1-6C) alkoxy- (1-6C) alkoxycarbonyl, (1-6C) alkylamino (2-6C) alkanoyl, di - [(1-6C) alkyl] amino (2-6C) alkanoyl, (1 -6C) alkanoylamino- (2-6C) alkanoyl, (1-6C) alkoxy- (1-6C) alkoxy- (2-6C) alkanoyl, heterocyclyl, heterocyclyl- (1-6C) alkyl, heteroaryl or heteroaryl- (1 -6C) alkyl, and any heterocyclyl group of R ¹ may optionally carry 1 or 2 oxo substituents; where any CH, CH ₂ or CH ₃ in any alkyl group present in the definition of R ⁴ that is attached to X ¹ or present in the definition of Q ¹ that is attached to X ² may possibly be replaced by an O atom or an SO ₂ group, and adjacent carbon atoms in the alkyl chain can optionally be separated by the insertion of C≡C groups in this chain; R ^{2 is} selected from halo, cyano, (1-8C) alkyl, (1-6C) alkoxy, (1-6C) alkylthio, (2-6C) alkanoyl, (1-6C) alkylamino, carbamoyl, N- (1- 6C) alkylcarbamoyl, N, N-di - [(1-6C) alkyl] carbamoyl, (1-6C) alkoxy- (1-6C) alkyl, hydroxy- (1-6C) alkyl, (1-6C) alkoxy - (1-6C) alkoxy, (1-6C) alkylamino (1-6C) alkyl or hydroxy- (1-6C) alkoxy; n is 0, 1 or 2, and when n is 2, the R ³ groups may be the same or different, and each R ³ group present is selected from hydrogen, fluoro, bromo, chloro, cyano, hydroxymethyl, methylcarbamoyl, OR ⁹ , trifluoromethyl, methyl or propyl, where R ⁹ represents methyl or trifluoromethyl; or a pharmaceutically acceptable salt thereof. 8. The pyridine derivative of formula I according to claim 1, where: W represents CH; J represents O; each of G ₁ , G ₂ , G _3, and G _{4 is} selected from CH and N, provided that no more than one of G ₁ , G ₂ , G _3, and G ₄ is N; ring A is phenyl, pyrazol-4-yl, pyridin-3-yl, thien-2-yl, thiazol-5-yl, 1H-1,2,3-triazol-4-yl or 3H-1,2, 3-triazol-5-yl ring, wherein said ring is substituted with hydroxymethyl, 2-hydroxyethyl, 3-hydroxypropyl, methoxymethyl, cyanomethyl, acetyl, 2-methoxyacetyl, 3-methoxypropionyl, 3-methoxy-2-methyl-propionyl, hydroxyacetyl, 2 -hydroxypropionyl, 2-aminoethyl, 2-methylaminoethyl, 3-methylaminopropylcarbamoyl, 2-methylaminoethylcarbamoyl, 2-dimethylaminoethyl-N-methylcarbamoyl, 2-aminoethoxy, 2-meth ilaminoetoksi, 3-aminopropoxy, 3-methylaminopropoxy, 4-metilaminobutoksi, 2-methoxyethoxy, etilsulfonilom, methylsulfonyl, methylsulfonyloxy, metilsulfamoilom, tsiklopropilsulfamoilom, dimetilsulfamoilom, 2-gidroksietilsulfamoilom, tsiklopropilsulfamoilom, methanesulfonamido, acetamido, carbamoyl, methylcarbamoyl, tsiklopropilkarbamoilom, 2-gidroksietilkarbamoilom, dimethylamino, 2-dimethylaminoethylcarbamoyl, 3-dimethylaminopropylcarbamoyl, 2-diethylaminoethylcarbamoyl, 3-diethylaminopropylcarbamoyl, cyano, cyanomethyl m, aminomethyl, dimethylaminomethyl, 2- (dimethylamino) ethoxy, 2- (diethylamino) ethoxy, 3- (dimethylamino) propoxy, 3- (diethylamino) propoxy, pyrrolidin-1-yl, pyrrolidin-3-yl, pyrrolidin-2- silt, piperazin-1-yl, piperidin-4-yl, piperidin-3-yl, pyrazol-3-yl, tetrahydropyran-2-yl, tetrahydropyran-4-yl, azetidinyl, 1,1-dioxotetrahydro-1,4- thiazinyl, imidazolinyl, azepanyl, 4-aminoazepan-1-ylcarbonyl, azepan-4-yloxy, 4- (4-piperidyl) piperidin-1-ylcarbonyl, 1H-imidazolyl, 1,4-diazepanyl, (1R, 5S) -8 -azabicyclo [3.2.1] octanyl, quinuclidinyl, (3R) -quin clidinyl, 3,4,4a, 5,6,7,8,8a-octahydro-2H-quinolinyl, 3,4,6,7,8,8a-hexahydro-1H-pyrrolo [2,1-c] pyrazinyl, 3,8-diazaspiro [5.5] undecan-3-ylcarbonyl, 2,8-diazaspiro [4.5] decan-8-ylcarbonyl, 3,9-diazaspiro [5.5] undecan-3-yl-carbonyl, (1S, 4S) - 3,6-diazabicyclo [2.2.1] heptan-6-ylcarbonyl, 3-aminoazetidin-1-ylcarbonyl, pyrrolidin-1-ylmethyl, (3S) -3-aminopiperidin-1-ylcarbonyl, (2S) -pyrrolidin-2- yl-methylcarbamoyl, 4,9-diazaspiro [5.5] undecan-4-ylcarbonyl, 2,3,3a, 4,6,6a-hexahydro-1H-pyrrolo [3,4-c] pyrrole-5-ylcarbonyl, (3R ) -3- (2-aminoethyl) -1-piperidylcarbonyl, piperidin-4-ylmethyl, 1-meth lpyrrolidin-3-yl, 1-methylpyrrolidin-3-ylmethyl, 1-methylpyrrolidin-3-ylmethoxy, pyrrolidin-3-yloxy, pyrrolidin-2-yloxy, 1-methylpyrrolidin-3-yloxy, 2- (1-methylpyrrolidin-3 -yl) ethoxy, 2-pyrrolidin-1-yl-ethyl, 3-pyrrolidin-1-yl-propyl, 2- (1-methyl-pyrrolidin-2-yl) ethoxy, 2- (1-methyl-pyrrolidin-2-yl) ethyl-carbamoyl, piperidin-3 -methylmethyl, 1-methyl-piperidin-3-yl, 1-methyl-piperidin-3-ylmethoxy, 1-methyl-piperidin-3-yloxy, piperidin-3-ylmethoxy, 2- (1-methyl-piperidin-3- il) ethoxy, 3- (1-methyl-piperidin-3-yl) propoxy, piperidin-3-ylcarbamoyl, (3R) piperidin-3-ylmethylcarbamoyl m, piperidin-4-yloxy, 1-methyl-piperidin-4-ylmethoxy, azetidin-3-ylmethyl, 2-azetidinyl-ethyl, 3-azetidinyl-propyl, 1-methyl-azetidin-3-yl, 1-methyl-azetidin-3- ylmethyl, 2- (3-hydroxy-pyrrolidin-1-yl) ethyl, 3- (3-hydroxy-pyrrolidin-1-yl) propyl, 3- (3-hydroxymethyl-pyrrolidin-1-yl) propyl, 3- ( 2-hydroxymethyl-pyrrolidin-1-yl) propyl, 2- (2-hydroxymethyl-pyrrolidin-1-yl) ethyl, 2- (4-hydroxypiperidin-1-yl) ethyl, 3- (4-hydroxypiperidin-1-yl ) propyl, 1-acetylpiperidin-4-yl, 1-methoxyacetylpiperidin-4-yl, 1-hydroxyacetylpiperidin-4-yl, 1-hydroxyacetylpiperide in-4-yl, 1- (2-hydroxypropionyl) piperidin-4-yl, 5- (methylcarbamoyl) -1-methyl-pyrrolidin-3-yl, 3-pyrrolidin-1-ylpropoxy, 2-pyrrolidin-1-yl-ethoxy 2- (1-methylpiperidin-2-yl) ethoxy, 3- (1,1-dioxotetrahydro-1,4-thiazin-4-yl) propoxy, 2- (piperazin-1-yl) ethyl, 2- (1 -methyl-piperazin-4-yl) ethoxy, 3- (1-methyl-piperazin-4-yl) propoxy, 2- (1-methyl-piperazin-4-yl) ethyl, 3- (1-methyl-piperazin- 4-yl) propyl, (1-methyl-piperazin-4-yl) carbonyl, 3- (1-sulfonyl-piperazin-4-yl) propoxy, 3- (1-methylsulfonyl-piperazin-4-yl) -propoxy, 1- (methylsulfonyl) piperidin-4-yl, 1- (cyclopropylsulfonyl) piperidi n-4-yl, 1- (methoxycarbonyl) piperidin-4-yl, 1- (methoxymethylcarbonyl) piperidin-4-yl, 3- (1,1-dioxotetrahydro-1,4-thiazin-4-yl) propoxy, ( 1R, 5S) -8-azabicyclo [3.2.1] octan-3-yloxy, [(2E) -4- (1,1-dioxidothiomorpholin-4-yl) but-2-en-1-yl] oxidanyl, ( 3R) -quinuclidin-8-ylcarbamoyl, morpholino, morpholinomethyl, 2-morpholinoethyl, 3-morpholinopropyl, 2-morpholinoethoxy, 3-morpholinopropoxy, 2- (2-morpholinoethoxy) ethoxy, 3 - [(3R, 5S) -dimethylpiperazin-1-yl] propoxy, (3S, 5S) -5- (methoxymethyl) pyrrolidin-3-yloxy, (3S, 4R) -3-methylaminotetrahydropyran-4-yloxy, 4- (2-pyridylmethyl) piperazin-1 -ilcarbo silt, 2-piperazin-4-ylethoxy, 2- (piperidin-4-yloxy) ethoxy, 2- (azetidin-3-yloxy) ethoxy, 3- (2,6-dimethylpiperazin-4-yl) propoxy, 1-methylpyrrolidine -3-yl-N-methylcarbamoyl, quinuclidinylcarbonyl, 2-imidazolin-1-yl-ethylcarbamoyl, 2- (piperidin-1-ylmethyl) piperidin-1-ylcarbonyl, 1-ethoxypiperidin-4-ylcarbamoyloyl, 2 1-yl-N-methylcarbamoyl, 2- (3-fluoropyrrolidin-1-yl) ethylcarbamoyl, 4- (2-dimethylaminoethyl) piperidin-1-ylcarbonyl, 2- (1-methylpiperidin-2-yl) -pyrrolidin-1- ilcarbonyl, 5- (morpholinylmethyl) pyrrolidin-1-ylcarbonyl, 5- (azepan-1-yl) pi rolidin-1-ylcarbonyl, 2- (3,3-difluoropyrrolidin-1-yl) ethylcarbamyl, 2- (3-fluoropyrrolidin-1-yl) ethylcarbamyl, 3,4,4a, 5,6,7,8,8a octahydro-2H-quinolin-4-ylcarbamoyl, 1-dimethylaminocyclohex-1-ylmethylcarbamoyl, 2-morpholinoethylcarbamoyl, 2-1H-imidazolylethylcarbamoyl, 1- (pyridin-3-yl-4-piperide il) piperazin-4-ylcarbonyl, 1,4-diazepanylcarbonyl, 1- (N-dimethylcarbamoylmethyl) piperazin-4-ylcarbonyl, 1- (carbamoylethyl) piperazin-4-ylcarbonyl, 3,4,6,7,8,8- hexahydro-1H-pyrrolo [2,1-c] pyrazin-1-ylcarbonyl, morpholine-4-carbonyl, morpholinos Ulphonyl, 4-hydroxypiperidin-1-carbonyl, 2-pyrrolidin-1-yl-ethylcarbamoyl, piperidin-1-yl, 4- (aminomethyl) piperidin-1-ylcarbonyl, 3-aminopyrrolidin-1-ylcarbonyl, 3-methyl-1-amylamino , piperidin-4-yl-N-methylcarbamoyl, 4-methylaminopiperidin-1-ylcarbonyl, 4- (piperazin-1-ylmethyl) piperidin-1-ylcarbonyl, 4-methylaminocyclohexylcarbonyl, pyrrolidin-3-yl-carbamyl ilpiperidin-1-ylcarbonyl, 1- (N, N-dimethylcarbamoylmethyl) piperazin-4-ylcarbonyl, 5- (N-methylcarbamoyl) pyrrolidin-3-yl, 1- (N, N-dimethylcarbamoylmethyl ) -piperidin-4-yl, 1- (methylcarbamoylmethyl) piperidin-4-yl, 1- (carbamoylmethyl) piperidin-4-yl, 1-isopropylpiperidin-4-yl, 1- (2-hydroxyethyl) piperidin-4-yl , 1- (N, N-dimethylaminomethylcarbonyl) -piperidin-4-yl, 1-methyl-4-piperidyl, 1-methylpiperidin-4-ylmethyl, 1- (2-methoxyethyl) piperidin-4-ylcarbamoyl, 1-ethyl- 4-piperidyl, 1-isopropyl-4-piperidyl, 1-piperidylmethyl, piperidin-4-carbonylamino, 4-methylpiperazin-1-carbonyl, 4-methylpiperazin-1-yl, 1- (4-methylpiperazin-1-ylcarbonyl) p -4-yl, 3-dimethylaminopropoxy, 1-tert-butoxycarbonyl-4-piperidium scrap or 1-methyl-1-oxide-piperidin-1-yl-4-yl, and is optionally substituted with one or more methyl, methoxy, ethoxy, fluoro, hydroxymethyl, methoxymethyl, ethoxymethyl, cyano, 1-hydroxyethyl, dimethylcarbamoyl, dimethylamino groups methylcarbamoyl, methylaminomethyl or carbamoyl; or ring A is quinolyl, 2,3-dihydro-1,4-benzodioxin-6-yl, 1H-indazol-5-yl, 1H-indol-5-yl, 1H-indol-6-yl, 1.3 -benzodioxol-5-yl or naphthyl, possibly substituted by any of the substituents listed for substitution with phenyl, pyrazol-4-yl, pyridin-3-yl, thien-2-yl, thiazol-5-yl, 1H-1,2 The 3-triazol-4-yl or 3H-1,2,3-triazol-5-yl rings above; n is 0, 1 or 2, and the groups (R ³ ) _n are selected from 4-fluoro, 5-fluoro, 6-fluoro, 6-bromo, 6-propan-2-yl, 5-bromo, 4,6-difluoro 6-chloro, 5-methyl, 6-methyl, 6-trifluoromethoxy, 5-trifluoromethyl, 6-methoxy, 7-methyl, 6,7-difluoro, 7-fluoro, 5-methoxy, 7-methoxy, 4-methoxy 4-cyano, 7-cyano, 7-hydroxymethyl or 7-methylcarbamoyl; or a pharmaceutically acceptable salt thereof. 9. The pyrazine derivative of formula I according to claim 1, where: W is N; J represents O; each of G ₁ , G ₂ , G ₃ and G ₄ represents CH; ring A is 1- (1-tert-butoxycarbonyl-4-piperidyl) pyrazol-4-yl, 1- (4-piperidyl) pyrazol-4-yl, 1- (1-methyl-4-piperidyl) pyrazol-4 -yl, 3- (dimethylsulfamoyl) phenyl, 3-piperazin-1-yl-phenyl, 6-piperazin-1-yl-3-pyridyl, 3- (1-piperidyl) phenyl, 3-pyrrolidin-1-ylphenyl, 4- ( morpholinomethyl) phenyl, 6- (4-methylpiperazin-1-yl) -3-pyridyl, 3-morpholinophenyl, 3-methylsulfonylphenyl, 3- (morpholinomethyl) phenyl, 4-piperazin-1-ylphenyl, 4- (dimethylsulfamoyl) phenyl, 3-ethylsulfonylphenyl, 3- (4-methylpiperazin-1-yl) phenyl, 3-dimethylaminophenyl, 3- (cyanomethyl) phenyl, 3- (methoxymethyl) phenyl, 3-methylsulfon onyloxyphenyl, 4- (cyanomethyl) phenyl, 3-methyl-1-piperidin-4-ylpyrazol-4-yl, 3-methyl-1- (1-methylpiperidin-4-yl) pyrazol-4-yl or 3- (carboxymethyl )phenyl; n is 0 or n is 1, and the group R ³ , if present, is fluoro; or a pharmaceutically acceptable salt thereof. 10. The compound of formula I according to claim 1, where: W represents CH; J represents O; each of G ₁ , G ₂ , G ₃ and G ₄ represents CH; Ring A is a pyrazol-4-yl ring which is substituted at position 1 with an R ¹ group and optionally substituted with one or two R ² groups, where the group R ^{1 is} selected from 2-hydroxyethyl, 3-hydroxypropyl, 4-hydroxybutyl, 2-methoxyethyl, 3-methoxypropyl, 4-methoxybutyl, 2-methylaminoethyl, 3-methylaminopropyl, 4-methylaminobutyl, 2-dimethylaminoethyl, 3-dimethylaminophen 4-dimethylaminobutyl, azetidin-3-yl, 1-methylazetidin-3-yl, 1-ethylazetidin-3-yl, pyrrolidin-3-yl, 1-methylpyrrolidin-3-yl, 1-ethylpyrrolidin-3-yl, 5- (N-methylcarbamoyl) pyrrolidin-3-yl, 1-methyl-5- (N-methylcarbamoyl) pyrrolidin-3-yl, piperidin-3-yl, 1-methylpiperidin-3-yl, 1-ethylpiperidin-3-yl, piperidin-4-yl, 1-methylpiperidin-4-yl, 1- ethylpiperidin-4-yl, 1-isopropylpiperidin-4-yl, 4-cyanomethylpiperidin-4-yl, 1- (carbamoylmethyl) piperidin-4-yl, 1- (N-methylcarbamoylmethyl) piperidin-4-yl, 1- (N , N-dimethylcarbamoylmethyl) -piperidin-4-yl, 1- (N, N-dimethylaminomethylcarbonyl) piperidin-4-yl, 1- (2-hydroxyethyl) piperidin-4-yl, 8-methyl-8-azabicyclo [3.2. 1] octan-3-yl, 1- (methoxycarbonyl) piperidin-4-yl, 1- (ethoxycarbonyl) piperidin-4-yl, 1- (tert-butoxycarbonyl) piperidin-4-yl, 1-acetylpiperidin-4-yl , 1- (2-hydroxyacetyl) piperidin-4-yl, 1- (2-hydroxypropionyl) piperidin-4-yl, 1- (2-methoxyacetyl) piperidin-4-yl, 1- (2-m toxipropionyl) piperidin-4-yl, 1- (3-methoxypropionyl) piperidin-4-yl, 1- [2- (2-methoxyethoxy) acetyl] piperidin-4-yl, 1- (2-methylaminoacetyl) piperidin-4 -yl, 1- (3-methylaminopropionyl) piperidin-4-yl, 1- (2-dimethylaminoacetyl) piperidin-4-yl, 1- (3-dimethylaminopropionyl) piperidin-4-yl, 1- (2-acetamidoacetyl) piperidine -4-yl, 1- (3-acetamidopropionyl) piperidin-4-yl, tetrahydropyran-4-yl, azetidin-3-ylmethyl, 1-methylazetidin-3-ylmethyl, 1-ethylazetidin-3-ylmethyl, pyrrolidin-3- methylmethyl, 1-methylpyrrolidin-3-ylmethyl, 1-ethylpyrrolidin-3-ylmethyl, piperidin-3-ylmethyl, 1-methylp Iperidin-3-ylmethyl, 1-ethylpiperidin-3-ylmethyl, piperidin-4-ylmethyl, 1-methylpiperidin-4-ylmethyl, 1-ethylpiperidin-4-ylmethyl, 2-azetidin-1-yl-ethyl, 3-azetidin-1- ilpropyl, 2-pyrrolidin-1-yl-ethyl, 3-pyrrolidin-1-yl-propyl, 2- (3-hydroxypyrrolidin-1-yl) ethyl, 3- (3-hydroxypyrrolidin-1-yl) propyl, 2- (2-hydroxymethylpyrrolidine -1-yl) ethyl, 3- (2-hydroxymethylpyrrolidin-1-yl) propyl, 2-morpholinoethyl, 3-morpholinopropyl, 2-piperidinoethyl, 3-piperidinopropyl, 2- (4-hydroxypiperidin-1-yl) ethyl, 3 - (4-hydroxypiperidin-1-yl) propyl, 2-piperazin-1-yl-ethyl, 3-piperazin-1-yl-propi and, 2- (4-methylpiperazin-1-yl) ethyl, 3- (4-methylpiperazin-1-yl) propyl, and where possible R ² groups are selected from 3-cyano, 3- or 5-methyl, 3- or 5-ethyl, 3,5-dimethyl, 3- or 5-hydroxymethyl, 3- (1-hydroxyethyl), 3- or 5-methoxymethyl, 3-methylaminomethyl, 3-dimethylaminomethyl, 3- or 5-methoxy, 3- or 5-ethoxy, 3-methylamino, 3-dimethylamino, 3-carbamoyl, 3- (N-methylcarbamoyl) and 3- (N , N-dimethylcarbamoyl); n is 0, or n is 1 or 2, and the (R ³ ) _n groups that are present are selected from 4-, 5-, 6- or 7-fluoro, 4,5-, 4,6-, 4,7 -, 5,6-, 5,7- or 6,7-difluoro, 4-, 5-, 6- or 7-chloro, 4,6-dichloro, 4-, 5-, 6- or 7-bromo, 4-, 5-, 6- or 7-cyano, 4-, 5-, 6- or 7-methyl, 4-, 5-, 6- or 7-ethyl, 4-, 5-, 6- or 7- isopropyl, 7-hydroxymethyl, 5- or 6-trifluoromethyl, 4-, 5-, 6- or 7-methoxy and 5- or 6-trifluoromethoxy; or each of G ₁ , G ₂ , G ₃ and G _{4 is} selected from CH and N, provided that only one of G ₁ , G ₂ , G ₃ and G ₄ is N, and where ring A is pyrazole - A 4-yl ring which is substituted at position 1 by the group R ¹ as defined immediately above, and possibly substituted by one or two groups R ² as defined directly above, and where n is 0, so that the group R ^{3 is} absent, or a pharmaceutically acceptable salt thereof. 11. The compound of formula I according to claim 1, where: W represents CH; J represents O; each of G ₁ , G ₂ , G ₃ and G ₄ represents CH; Ring A is a pyrazol-4-yl ring which is substituted at position 1 with an R ¹ group and optionally substituted with one or two R ² groups, where the group R ^{1 is} selected from 2-hydroxyethyl, 3-hydroxypropyl, 2-dimethylaminoethyl, 3-dimethylaminopropyl, azetidin-3-yl, 1-methylazetidin-3-yl, pyrrolidin-3-yl, 1-methylpyrrolidin-3-yl, 5- (N-methylcarbamoyl) pyrrolidin-3-yl, 1-methyl-5- (N-methylcarbamoyl) -pyrrolidin-3-yl, piperidin-3-yl, 1-methylpiperidin-3-yl, piperidin-4-yl , 1-methylpiperidin-4-yl, 1-ethylpiperidin-4-yl, 1-isopropylpiperidin-4-yl, 4-cyanomethylpiperidin-4-yl, 1- (carbamoylmethyl) piperidin-4-yl, 1- (N-methylcarbamoylmethyl ) piperidin-4-yl, 1- (N, N-dimethylcarbamoylmethyl) -piperidin-4-yl, 1- (2-hydroxyethyl) pi eridin-4-yl, 1- (N, N-dimethylaminomethylcarbonyl) piperidin-4-yl, 8-methyl-8-azabicyclo [3.2.1] octan-3-yl, 1- (methoxycarbonyl) piperidin-4-yl, 1- (tert-butoxycarbonyl) piperidin-4-yl, 1-acetylpiperidin-4-yl, 1- (2-hydroxyacetyl) piperidin-4-yl, 1- (2-hydroxypropionyl) piperidin-4-yl, 1- ( 2-methoxyacetyl) piperidin-4-yl, 1- (2-methoxypropionyl) piperidin-4-yl, azetidin-3-ylmethyl, 1-methylazetidin-3-ylmethyl, pyrrolidin-3-ylmethyl, 1-methylpyrrolidin-3-ylmethyl , 1-methylpiperidin-3-ylmethyl, piperidin-4-ylmethyl, 1-methylpiperidin-4-ylmethyl, 2-azetidin-1-yl-ethyl, 3-azetidin-1-ylpr saw, 2-pyrrolidin-1-yl-ethyl, 3-pyrrolidin-1-yl-propyl, 2- (3-hydroxy-pyrrolidin-1-yl) -ethyl, 3- (3-hydroxy-pyrrolidin-1-yl) -propyl, 2- (2-hydroxymethyl-pyrrolidin -1-yl) ethyl, 3- (2-hydroxymethylpyrrolidin-1-yl) propyl, 2-morpholinoethyl, 3-morpholinopropyl, 2-piperidinoethyl, 3-piperidinopropyl, 2- (4-hydroxypiperidin-1-yl) ethyl, 3 - (4-hydroxypiperidin-1-yl) propyl, 2-piperazin-1-yl-ethyl, 3-piperazin-1-yl-propyl, 2- (4-methyl-piperazin-1-yl) ethyl and 3- (4-methylpiperazin-1- silt) drank and where possible R ² groups are selected from 3-cyano, 3-methyl, 5-methyl, 3,5-dimethyl, 3-hydroxymethyl, 5-hydroxymethyl, 3- (1-hydroxyethyl), 3-methoxymethyl, 3-methylaminomethyl 3-methoxy, 5-methoxy, 3-ethoxy, 5-ethoxy, 3-dimethylamino, 3-carbamoyl, 3- (N-methylcarbamoyl) and 3- (N, N-dimethylcarbamoyl); n is 0, or n is 1 or 2, and the (R ³ ) _n groups present are selected from 4-fluoro, 5-fluoro, 6-fluoro, 7-fluoro, 4,6-difluoro, 6,7-difluoro, 6 -chloro, 5-bromo, 6-bromo, 4-cyano, 7-cyano, 5-methyl, 6-methyl, 7-methyl, 6-isopropyl, 7-hydroxymethyl, 5-trifluoromethyl, 4-, 5-, 6 - or 7-methoxy and 6-trifluoromethoxy; or each of G ₁ , G ₂ , G ₃ and G _{4 is} selected from CH and N, provided that only one of G ₁ , G ₂ , G ₃ and G ₄ represents N, and where ring A represents pyrazole A 4-yl ring which is substituted at position 1 by the group R ¹ as defined immediately above, and possibly substituted by one or two groups R ² as defined directly above, and where n is 0, so that the group R ^{3 is} absent, or a pharmaceutically acceptable salt thereof. 12. The compound of formula I according to claim 1, where: W represents CH; J represents O; each of G ₁ , G ₂ , G ₃ and G ₄ represents CH; ring A represents a pyrazol-4-yl ring, which is substituted at the 1-position the group R ¹ and optionally substituted by one group R ^2, wherein group R ¹ is selected from azetidin-3-yl, 1-methylazetidin-3-yl, pyrrolidin-3 -yl, 1-methylpyrrolidin-3-yl, piperidin-3-yl, 1-methylpiperidin-3-yl, piperidin-4-yl, 1-methylpiperidin-4-yl, 1-ethylpiperidin-4-yl, 1-isopropylpiperidine -4-yl, 1-acetylpiperidin-4-yl, 1- (2-hydroxyacetyl) piperidin-4-yl, 1- (N, N-dimethylaminomethylcarbonyl) -piperidin-4-yl, group 1- (2-hydroxyethyl) piperidin-4-yl), 1 - {(2S) - (2-hydroxypropionyl] piperidin-4-yl, 1-me tilpyrrolidin-3-ylmethyl and 1-methylpiperidin-4-ylmethyl, and wherein a possible R ² group is selected from 3-methyl, 5-methyl, 3-hydroxymethyl, 3-methoxy methyl, 3-methoxy, 5-methoxy, 3-ethoxy and 5-ethoxy; n is 0 or n is 1, and the group R ³ , if present, is selected from 4-fluoro, 5-fluoro, 7-fluoro, 4-cyano, 7-methyl and 7-methoxy; or a pharmaceutically acceptable salt thereof. 13. The compound of formula I according to claim 1, where: W represents CH; J represents O; each of G ₁ , G ₂ , G ₃ and G ₄ represents CH; ring A is 1- (1-methylpiperidin-4-yl) pyrazol-4-yl, 3-methyl-1-piperidin-4-ylpyrazol-4-yl, 3-methyl-1- (1-methylpiperidin-4- il) pyrazol-4-yl, 3-hydroxymethyl-1- (1-methylpiperidin-4-yl) pyrazol-4-yl, 3-methoxymethyl-1- (1-methylpiperidin-4-yl) pyrazol-4-yl, 3-methoxymethyl-1-piperidin-4-ylpyrazol-4-yl, 3-methoxymethyl-1- (1- (hydroxyacetyl) piperidin-4-yl) pyrazol-4-yl, 3-methoxymethyl-1- [1- [ (2S) -2-hydroxypropanoyl] piperidin-4-yl] pyrazol-4-yl, 3-methoxymethyl-1- (1- (N-methylcarbamoylmethyl) piperidin-4-yl) pyrazol-4-yl, 3-hydroxymethyl- 1- (1- (N, N-dimethylcarbamoylmethyl) -piperidin-4-yl) pyrazol-4 -yl, 3-methoxymethyl-1- (1- (N, N-dimethylaminomethylcarbonyl) piperidin-4-yl) pyrazol-4-yl, 3-methoxymethyl-1- (1- (2-hydroxyethyl) piperidin-4-yl ) pyrazol-4-yl or 3-hydroxymethyl-1- [1 - [(2S) -2-hydroxypropanoyl] piperidin-4-yl] pyrazol-4-yl; n is 0 or 1, and when n is 1, R ³ is 4-fluoro, 4-cyano or 7-methoxy; or a pharmaceutically acceptable salt thereof. 14. The compound of formula I according to claim 1, selected from any of the following compounds: 3- (1,3-benzoxazol-2-yl) -5- [1- (1-methylpiperidin-4-yl) -1H-pyrazol-4-yl] pyridin-2-amine; 3- (4-fluoro-1,3-benzoxazol-2-yl) -5- [1- (1-methylpiperidin-4-yl) -1H-pyrazol-4-yl] pyridin-2-amine; 3- (1,3-benzoxazol-2-yl) -5- (3-methyl-1-piperidin-4-yl-1H-pyrazol-4-yl) pyridin-2-amine; 3- (1,3-benzoxazol-2-yl) -5- [3-methyl-1- (1-methylpiperidin-4-yl) -1H-pyrazol-4-yl] pyridin-2-amine; {4- [6-amino-5- (1,3-benzoxazol-2-yl) pyridin-3-yl] -1- (1-methylpiperidin-4-yl) -1H-pyrazol-3-yl} methanol; 3- (1,3-benzoxazol-2-yl) -5- [3- (methoxymethyl) -1- (1-methylpiperidin-4-yl) -1H-pyrazol-4-yl] pyridin-2-amine; 3- (4-fluoro-1,3-benzoxazol-2-yl) -5- [3- (methoxymethyl) -1-piperidin-4-yl-1H-pyrazol-4-yl] pyridin-2-amine; {4- [6-amino-5- (4-fluoro-1,3-benzoxazol-2-yl) pyridin-3-yl] -1- (1-methylpiperidin-4-yl) -1H-pyrazol-3- sludge} methanol; 3- (4-fluoro-1,3-benzoxazol-2-yl) -5- [3- (methoxymethyl) -1- (1-methylpiperidin-4-yl) -1H-pyrazol-4-yl] pyridin-2 -amine; 2- (4- {4- [6-amino-5- (1,3-benzoxazol-2-yl) pyridin-3-yl] -3- (methoxymethyl) -1H-pyrazol-1-yl} piperidin-1 -yl) -2-oxoethanol; (2S) -1- (4- {4- [6-amino-5- (1,3-benzoxazol-2-yl) pyridin-3-yl] -3- (methoxymethyl) -1H-pyrazol-1-yl } piperidin-1-yl) -1-oxopropan-2-ol; 2- (4- {4- [6-amino-5- (1,3-benzoxazol-2-yl) pyridin-3-yl] -3- (methoxymethyl) -1H-pyrazol-1-yl} piperidin-1 -yl) -N-methylacetamide; 2- (4- {4- [6-amino-5- (1,3-benzoxazol-2-yl) pyridin-3-yl] -3- (hydroxymethyl) -1H-pyrazol-1-yl} piperidin-1 -yl) -N, N-dimethylacetamide; (2S) -1- (4- {4- [6-amino-5- (1,3-benzoxazol-2-yl) pyridin-3-yl] -3- (hydroxymethyl) -1H-pyrazol-1-yl } piperidin-1-yl) -1-oxopropan-2-ol; 2- [2-amino-5- [3- (methoxymethyl) -1- (1-methyl-4-piperidyl) pyrazol-4-yl] -3-pyridyl] -1,3-benzoxazole-4-carbonitrile; 2- [2-amino-5- [3-methyl-1- (1-methyl-4-piperidyl) pyrazol-4-yl] -3-pyridyl] -1,3-benzoxazole-4-carbonitrile; [4- [6-amino-5- (7-methoxy-1,3-benzoxazol-2-yl) -3-pyridyl] -1- (1-methyl-4-piperidyl) pyrazol-3-yl] methanol; 3- (7-methoxy-1,3-benzoxazol-2-yl) -5- [3- (methoxymethyl) -1- (1-methyl-4-piperidyl) pyrazol-4-yl] pyridin-2-amine; 1- [4- [4- [6-amino-5- (1,3-benzoxazol-2-yl) -3-pyridyl] -3- (methoxymethyl) pyrazol-1-yl] -1-piperidyl] -2 dimethylaminoethanone and 2- [4- [4- [6-amino-5- (1,3-benzoxazol-2-yl) -3-pyridyl] -3- (methoxymethyl) pyrazol-1-yl] -1-piperidyl] ethanol; or a pharmaceutically acceptable salt thereof. 15. A pharmaceutical composition comprising a compound of formula I or a pharmaceutically acceptable salt thereof according to any one of claims 1-14, together with a pharmaceutically acceptable diluent or carrier. 16. The compound of formula I or its pharmaceutically acceptable salt according to any one of claims 1 to 14 for use in therapy. 17. The use of a compound of formula I or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 14 in the manufacture of a medicament for use in the treatment or prevention of tumors that are sensitive to inhibition of AxI and / or c-Met receptor enzymes. 18. A method of treating or preventing a warm-blooded animal having tumors that are sensitive to inhibition of AxI and / or c-Met receptor enzymes, comprising administering to said animal an effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof according to any one of claims 1-14.